Showing 2411-2420 of 4947 results for "".
- Psoriasis Severity Linked to Diabetes Riskhttps://practicaldermatology.com/news/psoriasis-severity-linked-to-diabetes-risk/2457970/Psoriasis patients are more likely to develop Type 2 diabetes than their psoriasis-free counterparts, and this risk increases dramatically based on the severity of the disease, according to researchers from the Perelman School of Medicine at the University of
- Sonoma Pharmaceuticals Launches Loyonhttps://practicaldermatology.com/news/sonoma-pharmaceuticals-launches-loyon/2457971/Sonoma Pharmaceuticals, Inc. has begun US commercialization of the company’s new Loyon® product. Under the supervision of a healthcare practitioner, Loyon is intended to manage and relieve the scaling, erythema, and itching associated with various types of dermatoses including seborrhea
- Calling all Innovators: J & J Launches Digital Beauty QuickFire Challengehttps://practicaldermatology.com/news/calling-all-innovators-j-j-launches-digital-beauty-quickfire-challenge/2457975/Johnson & Johnson Innovation LLC, in collaboration with Johnson & Johnson Consumer Inc., is launching the Digital Beauty QuickFire Challenge. The challenge will encourage start-up companies to create the most novel, future-forward digital
- Long-Term Use of Lilly's Taltz Shows Efficacy Improvements in PsA for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitorshttps://practicaldermatology.com/news/long-term-use-of-lillys-taltz-shows-efficacy-improvements-in-psa-for-patients-with-prior-inadequate-response-or-intolerance-to-tnf-inhibitors/2457980/Patients with active psoriatic arthritis (PsA) treated with Taltz (ixekizumab), who were previously intolerant or had inadequate responses to TNF inhibitors, showed improvements in the signs and symptoms of PsA across treatment groups for up to 52 weeks, according to Eli Lilly and Company. Interi
- Sensus Healthcare Launches SRT-100 for Keloid Prevention and Treatment in Chinahttps://practicaldermatology.com/news/sensus-healthcare-launches-srt-100-in-china-for-keloid-prevention-and-treatment/2457985/Sensus Healthcare, Inc. launched the SRT-100™ in China for the treatment and prevention of keloids with Chindex Medical Limited. Sensus also announced the extension of its exclusive distribution agreement with Chindex M
- Study: PsO, RA Patients Prescribed Similar Drugs, But PsO Patients Face Higher Liver Disease Riskhttps://practicaldermatology.com/news/study-pso-ra-patients-prescribed-similar-drugs-yet-pso-patients-face-higher-liver-disease-risk/2457987/Compared to controls, patients with psoriasis (PsO) are at higher risk for serious liver disease than patients with rheumatoid arthritis, reports a in the Journal of Investigative Dermatology from researchers a
- Long-Term Fat Reduction Seen Following Treatment with BTL Vanquish, Vanquish MEhttps://practicaldermatology.com/news/long-term-fat-reduction-seen-following-treatment-with-btl-vanquish-vanquish-me/2457992/Abdominal fat reduction achieved via BTL Vanquish and Vanquish ME lasts for at least four years, according to new long-term data released by the company. Both devices use radiofrequency (RF) energy to reduce fat. The study evaluated 13 in
- Use of a New Holographic Hand Piece May Improve Picosecond Laser Treatment of Acne Scarshttps://practicaldermatology.com/news/study-adding-a-holographic-beam-splitter-to-picosecond-laser-improves-acne-scars/2457993/Incorporating a new holographic beam splitter in a picosecond laser may help improve the appearance of acne scars, according to a study published in Lasers in Surgery and Medicine (LSM). The paper was selecte
- Sun Dermatology Launches Absorica Tracker App to Help Patients Track Progresshttps://practicaldermatology.com/news/sun-dermatology-launches-absorica-tracker-app-to-help-patients-track-progress/2457999/Sun Pharma launched an Absorica Tracker App to help patients get the most out of their treatment. The easy-to-use interface is designed to help users to monitor their progress with Absorica (isotretinoin) treatment with features like medication and appointment reminders, monthly tips and checklis
- Ortho Dermatologics: Long-term Efficacy Data for Siliqhttps://practicaldermatology.com/news/ortho-dermatologics-long-term-efficacy-data-for-siliq/2458009/Siliq™ (brodalumab) injection provided sustained high levels of skin clearance (PASI 100) over more than two years in patients with moderate-to-severe psoriasis, according to data presented at the 2017 Fall Clinical Dermatology Conference in Las Vegas and reported by